Mosaic Trial for Stem Cell Transplant Recipients (NCT06960993)
Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.
Who can join: Review the eligibility criteria below.
Location: Georgetown University School of Medicine — Washington D.C., District of Columbia
Age range: 18 Years
🧪 Interventions in This Study
- Intervention website (BEHAVIORAL)
- Enhanced Usual Care (Control) Website (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Georgetown University School of Medicine — Washington D.C., District of Columbia
- Northwestern University Feinberg School of Medicine — Chicago, Illinois
- Hackensack Meridian Health — Nutley, New Jersey
📞 Contact the Study Coordinator
Phone: (312) 503-3577
Email: Alex.psihogios@northwestern.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Malignancy
- A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors — Boston, Massachusetts
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation — New York, New York
- Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity — Winston-Salem, North Carolina
- Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation — Seattle, Washington
- Critical Care Outcomes of Hematologic Oncology Patients — Calgary, Alberta
- Expressive Writing Program Among Young Adults With Blood Cancer — Washington D.C., District of Columbia
Explore by condition: All Hematologic Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.